Compositions and methods for gene therapy

• US 20030212022A1
• Filed: 12/12/2002
• Published: 11/13/2003
• Est. Priority Date: 03/23/2001
• Status: Abandoned Application

• Current Assignee: Biosphere Medical Inc. (Merit Medical Systems, Inc.)
• Original Assignee: Biosphere Medical Inc. (Merit Medical Systems, Inc.)
• Inventors: Boschetti, Egisto, Vogel, Jean-Marie
• Application Number:
  US10/220,983
• Publication Number:
  US 20030212022A1
• Time in Patent Office: Days
• US Class Current: 514/44
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 48/0008 characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
• CPC Class Codes: A61K 48/0041 the non-active part being polymeric
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/1635 obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates

Abstract

The present invention relates to injectable compositions comprising biocompatible, swellable, substantially hydrophilic, non-toxic and substantially spherical polymeric material carriers which are capable of efficiently delivering bioactive therapeutic factor(s) physically linked to a transfection agent for use in embolization gene therapy. The present invention further relates to methods of embolization gene therapy, particularly for the treatment of angiogenic and non-angiogenic-dependent diseases, using the injectable compositions.

Claims

1. A composition suitable for administration to a mammal which comprises:

(a) a carrier of polymeric material;

(b) a bioactive therapeutic factor; and

(c) a transfection agent.

2. The composition of claim 1 wherein the polymeric material is associated with the bioactive therapeutic factor via the transfection agent.

3. The composition of claim 1, wherein the polymeric material is a microparticle.

4. The composition of claim 1, wherein the polymeric material is poly(ethylenevinyl acetate), poly (lactic acid) oligomers and polymers, polysaccharides, polyacrylates, polyacrylic acids, polyacrylamides, poly (anhydrides), silicones, vinyl alcohol polymers or combinations or mixtures thereof.

60. A method of treating an angiogenisis-dependent disease which comprises administering to a human having said disease a composition of claim 1.

73. The method of claim 60, wherein said method is employed prior to, during or after surgery.

5. A composition suitable for active embolization which comprises:

(a) a cross-linked substantially hydrophilic polymeric material suitable for embolization;

(b) a bioactive therapeutic factor; and

(c) a transfection agent.

6. The composition of claim 5, wherein the bioactive therapeutic factor is a polynucleotide.

7. The composition of claim 5, wherein the transfection agent is a lipopolyamine.

8. The composition of claim 5, wherein the polymeric material is sodium acrylate polymer, sodium acrylate and vinyl alcohol copolymer, acrylamides and acrylamide derivatives, saponification products of copolymer of vinyl acetate and acrylic acid ester, vinyl acetate and acrylic acid ester copolymer, vinyl acetate and methyl maleate copolymer, isobutylene-maleic anhydride crosslinked copolymer, starch-acrylonitrile graft copolymer and its saponification products, crosslinked sodium polyacrylate polymer, crosslinked polyethylene oxide, or combinations thereof.

9. The composition of claim 5, wherein the cross-linker is tetraethylene glycol diacrylate, tetraethylene glycol dimethacrylate, ethylene glycol dimethacrylate, pentaerythritol dimethacrylate, methylene bis acrylamide, methylene bis methylacrylamide, diallyltartradiamide, or any combination thereof.

10. The composition of claim 5, wherein the polymers comprise from about 0.5% to about 20%, by molecular weight, of crosslinkers.

11. The composition of claim 5, wherein the polymeric material is a microsphere.

12. The composition of claim 5, wherein the polymeric material is catonic or anionic.

13. The composition of claim 11, wherein the polymeric material is swellable.

14. The composition of claim 5, wherein the polymeric material further comprises a contrast agent.

15. The composition of claim 13, wherein the diameter of the polymeric material ranges from about 10 μ

m to about 2000 μ

m.

16. The composition of claim 15, wherein the diameter of the polymeric material ranges from about 50 μ

m to about 300 μ

m.

17. The composition of claim 13, wherein diameter of the polymeric material ranges from about 10 μ

m to about 400 μ

m before swelling.

18. The composition of claim 13, wherein the diameter of the polymeric material ranges from about 10 μ

m to about 200 μ

m before swelling.

19. The composition of claim 13, where diameter of the polymeric material ranges from about 10 μ

m to about 2000 μ

m after swelling.

20. The composition of claim 5, wherein the transfection agent is lipophilic.

21. The composition of claim 5, wherein the transfection agent is quaternary ammonium amphiphile (dioleoyloxypropyl) trimethylammonium bromide (commercialized as Lipofectin by GIBCO-BRL), lipophilic glutamate diesters with pendent trimethyl ammonium heads, metabolizable parent lipids DOGS (Transfectam®

, Biosphere Medical) and DPPES, polyethylenimine (PEI), metabolizable quaternary ammonium salts (DOTB, DOTAP (Boehringer, Mannheim), dioleoyl esters, ChoTB, ChoSC, DOSC), DC-Chol, DOPE/DC-Chol in one to one mixtures, the polyamines spermine and spermidine, lipopolyamines, lipophilic polylysines (LPLL), DEBDA hydroxide with excess phosphatidylcholine/cholesterol, CTAB/DOPE mixtures, lipophilic diester of glutamic acid (TMAG) with DOPE, CTAB, DEBDA, DDAB, and stearylamine in admixture with phosphatidylethanolamine, DDAB/DOPE (TransfectACE, GIBCO BRL), or oligogalactose bearing lipids.

22. The composition of claim 5, wherein bioactive therapeutic factor comprises genetic material.

23. The composition of claim 22, wherein the genetic material comprises polynucleotides, RNA and DNA, antisense RNA and DNA, hammerhead RNA, or ribozymes or combinations thereof.

24. The composition of claim 23, wherein the polynucleotide expresses an antiangiogenic factor.

25. The composition of claim 23, wherein the polynucleotide expresses an antimitotic factor.

26. The composition of claim 5, wherein the polymeric material further comprises an anti-inflammatory or anti-angiogenic compound.

27. A pharmaceutical composition suitable for embolization and gene therapy upon administration to a human which comprises the composition of claim 11.

28. The pharmaceutical composition of claim 27, wherein the composition is implantable.

29. The pharmaceutical composition of claim 27, wherein the composition is injectable.

30. The composition of claim 29, where the pharmaceutical composition is injectable through a needle of about 18 gauge or smaller.

31. The microsphere of claim 11, wherein the bioactive therapeutic factor is p53 and the transfection agent is a lipopolyamine.

32. An injectable pharmaceutical composition comprising the composition of claim 5 and a biocompatible carrier.

33. The composition of claim 30, wherein the composition comprises the polymeric material in an amount from about 10% to about 90% by weight and the biocompatible carrier in an amount from about 10% to about 90% by weight.

34. The composition of claim 31, wherein the composition comprises the polymeric material in an amount from about 10% to about 50% by weight and the biocompatible carrier in an amount from about 50% to about 90% by weight.

35. The composition of claim 32, wherein the composition is a suspension of said polymeric material in said biocompatible carrier.

36. The composition of claim 32, wherein the biocompatible carrier is in an emulsion.

37. The composition of claim 32, wherein the biocompatible carrier is in an organic or non-aqueous solution.

38. The composition of claim 32, wherein the biocompatible carrier is in an aqueous based solution, a hydro-organic solution, or mixtures thereof.

39. The composition of claim 32, wherein the biocompatible carrier comprises salts composed of cations selected from the group consisting of sodium, potassium, calcium, magnesium, iron, zinc, and ammonium in an amount of from about 0.01 M to about 5 M.

40. The composition of claim 39, wherein the salt is supplied in form of a contrast agent.

41. The composition of claim 24, wherein the contrast agent is monomeric (acrylamido-3-propionamido)-3-triiodo-2,4,6-benzoic acid.

61. A method of treating an angiogenisis-dependent disease which comprises administering to a human having said disease a composition of claim 5.

67. A kit having the components (a) and (b) of claim 61 in one vial.

74. The method of claim 61, wherein said method is employed prior to, during or after surgery.

42. A method for delivering to a mammalian host a polynucleotide which comprises administering to a mammal having a disease a substantially hydrophilic polymeric material associated with a polynucleotide and a transfection agent.

43. The method of claim 42, wherein the administration of said substantially hydrophilic polymeric material associated with a polynucleotide and a transfection agent is for gene therapy.

44. The method according to claim 42, wherein the polymeric material comprises cross-linked substantially hydrophilic polymers or copolymers.

45. The method according to claim 42, wherein said disease is associated with angiogenesis.

46. The method according to claim 42, wherein said disease is a cancer associated with angiogenesis.

47. The method according to claim 42, wherein the disease is a solid tumor.

48. The method according to claim 47, wherein the tumor is associated with the liver, kidney, acute lymphoblastic leukemia, acute myeloid leukemia, ewing'"'"'s sarcoma, gestational trophoblastic carcinoma, hodgkin'"'"'s disease, non-Hodgkin'"'"'s lymphoma, burkitt'"'"'s lymphoma diffuse large cell lymphoma, follicular mixed lymphoma, lymphoblastic lymphoma, rhabdomyosarcoma, testicular carcinoma, wilms'"'"'s tumor, anal carcinoma, bladder carcinoma breast carcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, head and neck carcinoma, lung (small cell) carcinoma, multiple myeloma, Non-Hodgkin'"'"'s lymphoma, follicular lymphoma, ovarian carcinoma, brain tumors (astrocytoma), cervical carcinoma, colorectal carcinoma, hepatocellular carcinoma, kaposi'"'"'s sarcoma, lung (non-small-cell) carcinoma, melanoma, pancreatic carcinoma, prostate carcinoma, soft tissue sarcoma, breast carcinoma, colorectal carcinoma (stage III), osteogenic sarcoma, ovarian carcinoma (stage III), testicular carcinoma, or combinations thereof.

49. The method according to claim 42, wherein the polymeric material microsphere is of a size sufficient to embolize the vessels at the site of administration.

50. The method according to claim 42, wherein the polymeric material is not of sufficient size to embolize sufficient to embolize the vessels at the site of administration but is sufficient to anchor in the tumor.

51. The method according to claim 42, wherein the route of administration is directly into tumor.

52. The method according to claim 42, wherein the route of administration is into tumor vasculature.

53. The method according to claim 42, wherein the mammal is human.

70. The method of claim 42, wherein said method is employed prior to, during or after surgery.

71. The method of claim 43, wherein said method is employed prior to, during or after surgery.

76. The method of claim 42, wherein said method is employed prior to, during or after surgery.

54. A method for active embolization in a mammal host which comprises administering to a mammal having an angiogenesis dependent disease a substantially hydrophilic polymeric material associated with a bioactive therapeutic factor capable of expression of an anti-angiogenic material, wherein said bioactive therapeutic factor is associated with a transfection agent.

55. The method of claim 54, wherein said polymeric material further comprises contrast media.

56. The method of claim 54, wherein said polymeric material further comprises other therapeutics including anti-angiogenic compounds, anti-inflammatory drugs, antibacterial drugs, and anti-histamine drugs, or combinations thereof.

57. The method of claim 54, wherein said bioactive therapeutic factor is a polynucleotide encoding p53.

58. The method of claim 54, wherein said transfection agent is a lipophilic transfection agent.

59. The method of claim 54, wherein said disease is a tumor associated with the liver, kidney, acute lymphoblastic leukemia, acute myeloid leukemia, ewing'"'"'s sarcoma, gestational trophoblastic carcinoma, hodgkin'"'"'s disease, non-Hodgkin'"'"'s lymphoma, burkitt'"'"'s lymphoma diffuse large cell lymphoma, follicular mixed lymphoma, lymphoblastic lymphoma, rhabdo myosarcoma, testicular carcinoma, wilms'"'"'s tumor, anal carcinoma, ladder carcinoma breast carcinoma, chronic lymphocytic leukemia, chronic myelogenous leukemia, hairy cell leukemia, head and neck carcinoma, lung (small cell) carcinoma, multiple myeloma, Non-Hodgkin'"'"'s lymphoma, follicular lymphoma, ovarian carcinoma, rain tumors (astrocytoma), cervical carcinoma, colorectal carcinoma, hepatocellular carcinoma, kaposi'"'"'s sarcoma, lung (non-small-cell) carcinoma, melanoma, pancreatic carcinoma, prostate carcinoma, soft tissue sarcoma, breast carcinoma, colorectal carcinoma (stage III), osteogenic sarcoma, ovarian carcinoma (stage III), testicular carcinoma, or combinations thereof.

72. The method of claim 54, wherein said method is employed prior to, during or after surgery.

62. A kit for performing embolization gene therapy comprising:

(a) a suspension of microspheres suitable for embolization; and

(b) a transfection agent suitable for delivering genetic material to a cell.

63. A kit according to claim 62, wherein the polymeric material is contained within one vial and the transfection agent associated with a polynucleotide which encodes the bioactive therapeutic factor is contained within another vial, and wherein the contents of both vials are mixed together to form the pharmaceutical composition.

64. A kit according to claim 62, wherein the polymeric material is contained within one vial, the transfection agent is contained within another separate vial, and the polynucleotide which encodes the bioactive therapeutic factor is contained within another separate vial, wherein the contents of all three vials are mixed together to form the pharmaceutical composition.

65. The kit of claim 62, which further comprises a bioactive therapeutic factor.

66. The kit of claim 62, wherein said microspheres are dry and ready for hydration.

68. A method for active embolization in a mammal host which comprises administering to a mammal having a disease a substantially hydrophilic polymeric material associated with a bioactive therapeutic factor, wherein said bioactive therapeutic factor is associated with a transfection agent.

75. The method of claim 68, wherein said method is employed prior to, during or after surgery.

69. A microparticle suitable for active embolization which comprises a polymeric material capable of embolizing a blood vessel, wherein said polymeric material is linked to a transfection agent which is linked to a genetic material.

77. A method for delivering to a mammalian host a polynucleotide which comprises administering to a mammal having a disease a substantially hydrophilic polymeric material associated with a polynucleotide and a transfection agent, and wherein said polymeric material is delivered to the site of action by the use of targeting antibodies.

78. A method for active embolization in a mammal host which comprises administering to a mammal having an angiogenesis dependent disease a substantially hydrophilic polymeric material associated with a bioactive therapeutic factor capable of expression of an anti-angiogenic material, wherein said bioactive therapeutic factor is associated with a transfection agent, and wherein said polymeric material is delivered to the site of action by the use of targeting antibodies.